Perenyi A, Gardos G, Samu I, Kallos M, Cole J O
Clin Neuropharmacol. 1983 Mar;6(1):55-61. doi: 10.1097/00002826-198303000-00006.
An antiparkinson drug (APK) withdrawal study was carried out in 34 schizophrenic outpatients on maintenance neuroleptics. Sixty-five percent of patients were without major complaints after 2 weeks of APK discontinuation, while 35% reported adverse effects including extrapyramidal, autonomic, and behavioral symptoms. Male patients and those on higher diethazine doses before withdrawal reported more complaints. Ratings showed significant increases of parkinsonism, as well as dyskinesia following APK withdrawal. No clinical evidence was obtained in support of the notion of cholinergic hypersensitivity in patients showing "tremors" at baseline.
对34名正在服用维持剂量抗精神病药物的精神分裂症门诊患者进行了一项抗帕金森药物（APK）撤药研究。65%的患者在停用APK 2周后无主要不适，而35%的患者报告了包括锥体外系、自主神经和行为症状在内的不良反应。男性患者以及撤药前服用较高剂量二乙嗪的患者报告的不适更多。评分显示，撤药后帕金森症以及运动障碍显著增加。对于基线时出现“震颤”的患者，未获得支持胆碱能超敏概念的临床证据。
